Trans-scleral drug delivery method and apparatus

• US 7,276,050 B2
• Filed: 03/02/2004
• Issued: 10/02/2007
• Est. Priority Date: 03/02/2004
• Status: Expired due to Fees

• Current Assignee: RFE Pharma LLC
• Original Assignee: Alan Franklin
• Inventors: Franklin, Alan
• Primary Examiner(s): Sirmons; Kevin C.
• Assistant Examiner(s): WITCZAK, CATHERINE
• Application Number:
  US10/791,487
• Publication Number:
  US 20050197637A1
• Time in Patent Office: 1,309 Days
• Field of Search: 604/289, 604/521, 604/294, 604/890.1, 604/891.1, 604/93.01, 424/423, 424/424, 424/427, 424/428
• US Class Current: 604/294
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/4192 1,2,3-Triazoles
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

A method of treating ocular disorders involving angiogenesis includes the steps of providing a trans-scleral drug delivery device comprising an insert stabilizer for attachment to a scleral surface and having an interlock opening and a replaceable implant having a reservoir adjacent the scleral surface and an interlock tab, wherein said insert stabilizer and said replaceable implant are removeably connectable by mating said interlock tab and said interlock opening; providing an anti-angiogenic factor; introducing said anti-angiogenic factor into said reservoir; and attaching said insert stabilizer to the scleral surface. The reservoir can be refilled by disengaging the implant from the stabilizer, inserting a new dosage of anti-angiogenic factor, and reconnecting the implant to the stabilizer or injecting a new dosage of anti-angiogenic factor into the reservoir through an injection port in the stabilizer.

Claims

1. A method of treating ocular disorders involving angiogenesis, comprising the steps of:

providing a trans-scleral drug delivery device comprising;

an insert stabilizer for attachment to a scleral surface and having an interlock opening and an injection port;

a removable and refillable implant having a reservoir adjacent the scleral surface and an interlock tab, wherein said insert stabilizer and said removable and refillable implant are removeably connectable by mating said interlock tab and said interlock opening and wherein said injection port communicates with said reservoir;

providing an anti-angiogenic factor;

introducing said anti-angiogenic factor into said reservoir;

attaching said insert stabilizer to the scleral surface; and

refilling said trans-scleral drug delivery device alternately and selectively by

disengaging said removable and refillable implant from said insert stabilizer, placing a new dosage of angiogenic factor in a pellet form in said reservoir, and re-interlocking said removable and refillable implant with said insert stabilizer, and

injecting a new dosage of angiogenic factor in liquid form in said reservoir through the injection port.

2. The method of treating ocular disorders as set forth in claim 1, wherein the anti-angiogenic factor is carboxyamido-triazole (CAI).

3. A method of treating ocular disorders involving angiogenesis, comprising the steps of:

providing a trans-seleral drug delivery device comprising;

an insert stabilizer for attachment to a scleral surface and having an interlock opening;

a removable and refillable implant having a reservoir adjacent the scleral surface and an interlock tab;

interlocking said insert stabilizer and said removable and refillable implant by connecting said interlock tab and said interlock opening;

providing a pellet of carboxyamido-triazole; and

placing said pellet in said reservoir;

attaching said insert stabilizer to the scleral surface; and

refilling said trans-scleral drug delivery device by disengaging said removable and refillable implant from said insert stabilizer, placing a second pellet of carboxyamido-triazole in said reservoir, and re-interlocking said implant with said insert stabilizer.